Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on eye care therapies in the United States. Its lead product is XDEMVY, a lotilaner ophthalmic solution approved for the treatment of demodex blepharitis, a condition caused by Demodex mite infestation. The company markets its products through specialty pharmacies and distributors, and it also serves clinics, hospitals, pharmacies, and federal healthcare programs.
Beyond its commercial product, Tarsus is developing additional candidates in its lotilaner-based pipeline. TP-04 is in Phase 2 development as a sterile aqueous gel for ocular rosacea, while TP-05 is being studied as an oral tablet for the prevention of Lyme disease and is also in preclinical work related to community malaria reduction. The company is further advancing lotilaner as an active pharmaceutical ingredient for potential use in eye care and infectious disease prevention. Tarsus was incorporated in 2016 and is headquartered in Irvine, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TARS
|
$62.52
|
10.9% Upside
|
Fair
|
$94.56
|
67.7% Upside
|
Bargain
|
Good
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-50.6x
|
7.0x
|
4.6x
|
2.42 B
|
2.142 B
|
3.5%
|
74.6%
|
6.7
|
—
|
65.3%
|
